J&J's 2018 Remicade patent smacked down at PTO again

Johnson & Johnson ($JNJ) said the U.S. Patent and Trademark Office rejected a 2018 Remicade patent for the second time, putting the blockbuster anti-inflammatory's exclusivity in jeopardy. But the company also said it would appeal, a process that could take years. Release